Pokeweed antiviral protein (PAP), a 29-kDa protein isolated from Phytolacca americana inhibits translation by catalytically removing a specific adenine residue from the 28S rRNA of eukaryotic ribosomes. PAP has potent antiviral activity against many plant and animal viruses, including human immunodeficiency virus. We describe here development of a positive selection system to isolate PAP mutants with reduced toxicity. In vitro translation in the presence or absence of microsomal membranes shows that PAP is synthesized as a precursor and undergoes at least two different proteolytic processing steps to generate mature PAP.
The PAP expression plasmid was mutagenized and plasmids encoding mutant PAP genes were identified by their failure to kill S. cerevisiae. A number of mutant alleles were sequenced. In one mutant, a point mutation at Glu-177 inactivated enzymatic function in vitro, suggesting that this glutamic acid residue is located at or near the catalytic site. Mutants with either point mutations near the N terminus or a nonsense mutation at residue 237 produced protein that was enzymatically active in vitro, suggesting that the toxicity of PAP is not due solely to enzymatic activity. Toxicity of PAP appears to be a multistep process that involves possibly different domains of the protein.
Pokeweed antiviral protein (PAP), a ribosome-inactivating protein (RIP) isolated from the leaves or seeds of Phytolacca americana, catalytically removes a specific adenine residue from a highly conserved stem-loop structure in the 28S rRNA of eukaryotic ribosomes (1, 2) . This lesion interferes with elongation factor 2 binding and blocks protein synthesis. PAP was discovered when pokeweed extracts were found to inhibit the transmission of tobacco mosaic virus and was subsequently demonstrated to be equally effective against a number of other plant viruses (3) . Studies that compare the relative antiviral properties of a number of RIPs showed that all of the RIPs tested had antiviral activity, but none was as effective as PAP (4) . PAP has been shown to inhibit infection of both Vero and HeLa cells by herpes simplex virus (5) and to inhibit human immunodeficiency virus 1 (HIV-1) replication in T cells and macrophages infected in vitro at concentrations that do not inhibit cellular protein synthesis (6) . A number of recent studies have shown that conjugating PAP with monoclonal antibodies dramatically increases its potency against cells infected with HIV and human cytomegalovirus (7) . In addition, PAP has been used as the cytotoxic moiety of immunotoxins against acute lymphoblastic leukemia and PAPcontaining immunotoxins have shown significant antileukemic activity in clinical trials (7) .
Single-chain RIPs (type I RIPs), like PAP, are poorly characterized at the molecular level compared to the type II RIP, ricin, which consists of an enzymatically active A chain joined to a galactose-binding lectin (B chain) through a single disulfide bond. Although all RIPs inactivate ribosomes from animals, the efficacy of ribosome inactivation of fungal, protozoan, plant, and prokaryotic ribosomes varies between RIPs. For example, ricin is 23,000 times more effective on rat liver ribosomes than on plant ribosomes (8), while PAP is equally active on ribosomes from all five kingdoms. Three distinct antiviral proteins with similar activities have been identified in pokeweed (7) . Recently, we have cloned the cDNA encoding the spring leaf form (PAP) and showed that its expression in transgenic plants leads to broad spectrum resistance to viral infection (9) . The mechanism by which PAP inhibits viral infection or kills cells is not understood. We describe here the isolation of PAP mutants with reduced toxicity and the molecular and biochemical analysis of these mutants. Nucleotide Sequence Analysis. Plasmids were isolated from the mutants, transformed into Escherichia coli (13) , and sequenced using the Sequenase 2.0 DNA sequencing kit (United States Biochemical) (14) .
MATERIALS AND METHODS

Construction
Enzymatic Activity of PAP Mutants. In vitro translation of brome mosaic virus (BMV) RNA with a modified rabbit reticulocyte lysate was carried out in the presence of protein extracts from yeast as described (9) . PAP levels in yeast were quantitated by ELISA (9) (12) and transformed into yeast; cells were plated on medium containing glucose and replica plated on galactose-containing plates.
In the presence of 2% raffinose, a nonrepressing, noninducing carbon source relative to GAL gene expression, the growth of yeast transformants containing NT123 or NT124 was indistinguishable from the transformants containing the vector alone. Growth of transformed yeast, containing NT123 was arrested upon addition of the inducer galactose to the medium (Fig. 3) Growth of the mutants derived from NT123 on galactosecontaining medium was indistinguishable from growth on raffinose-containing medium (Fig. 3) . Similar results were obtained with mutants derived from NT124. Analysis of protein accumulation in yeast indicated that expression of the wild-type PAP, but not the hydroxylamine-generated mutant PAP, resulted in decreased protein accumulation in yeast (data not shown). After mutagenesis, the colonies growing on Ura-galactose plates were analyzed for PAP expression by ELISA using PAP antibodies and the positives were further analyzed by immunoblot analysis. Of a total of 28 mutants isolated from NT123 mutagenesis, six different isolates expressed proteins that cross-reacted with PAP antibodies. Of 44 mutants isolated from NT124 mutagenesis, 24 different isolates produced proteins that cross-reacted with PAP antibodies. Fig. 4 shows an immunoblot of protein extracted from the yeast mutants. Some of the mutants (HMNT123-1, -124-6, -124-7, and -124-1) produced proteins that were larger than the mature form of PAP (29 kDa), suggesting that processing of PAP to the mature form is blocked in these mutants. Two mutants produced proteins that comigrated with the mature form of PAP (HMNT123-2 and -123-3), while several others produced smaller proteins (HMNT123-4, -123-5, -124-2, and -124-3). Protein expression levels in the mutants ranged from 0.005% to 0.08% of total soluble protein.
Nucleotide Sequence Analysis of PAP Mutants. The positions of the amino acid alterations in the PAP mutants were identified by sequence analysis of the plasmids rescued from yeast. Sequence analysis of HMNT123-2 revealed that it contains a single point mutation, changing the glutamic acid at position 176 to valine (E176V) at the putative active site ( Table  1) . As shown in Fig. 4, HMNT123-2 Trp-237 (TGG) -Stop (TAG) Leu-202 (CTT) -Phe (TTT) of PAP (15) . HMNT123-6, HMNT124-2, and HMNT124-3 all had a point mutation near the C terminus that introduced a stop codon instead of a tryptophan at position 237 (W237) ( Table 1) . As a result of this mutation, 25 amino acids were deleted from the C terminus of the mutant PAP, and a truncated protein was produced (Fig. 4, lane 11) . HMNT123-5 contained a frameshift mutation that deleted the last 2 nucleotides of the glutamic acid codon at position 184 and created a stop codon at asparagine-190, resulting in expression of a truncated protein (lane 6). A point mutation in HMNT124-1 changed the glutamic acid at position 97 to lysine (E97K) ( Table 1) . HMNT123-1 also contained a single point mutation at position 75, changing glycine to valine (G75V). Both of these mutants expressed a larger protein than purified PAP (lanes 2 and 9), suggesting that processing of PAP is inhibited in these mutants.
To confirm that the observed mutant phenotypes were due to the mutations identified in the PAP sequence, and not to a chromosomal mutation, each mutant PAP plasmid was isolated and retransformed into the host strain, W303, and URA I transformants were selected. These transformants grew at wild-type rates on galactose-containing medium, indicating that the ability of the transformants to survive induction of PAP expression is plasmid linked.
Enzymatic Activity of PAP Mutants. An in vitro translation assay was used to compare the enzymatic activity of PAP -1 and 124-3) . mutants. BMV RNA was translated in the rabbit reticulocyte lysate system (Promega) in the presence of extracts from yeast containing different amounts of PAP. The protein synthesis inhibition assay was carried out in the presence of 0.1 or 0.2 ng of PAP per ml from yeast. The inhibition curves were linear in the range of 0.1 to 1 ng of PAP per ml. Fig. 5 shows inhibition of protein synthesis in the presence of 0.2 ng of PAP per ml from yeast containing the wild-type or the mutant PAPs. The background level of incorporation is shown in the RNA column when BMV RNA is not included in the reaction mixture. In previous experiments, when in vitro translation was performed in the presence of bovine serum albumin (0.2 ng/ml), no inhibition of translation was observed. When protein from nontransformed yeast (WT) was added, a slight inhibition of translation was observed (Fig. 5) . Translation was inhibited in the presence of purified PAP added to wild-type yeast extract (WT+PAP), protein extracts from yeast containing NT123 or NT124, and protein extracts from yeast containing the hydroxylamine-generated mutants HMNT123-3, HMNT124-1, and HMNT124-3. In contrast, protein extracted from HMNT123-2 did not inhibit protein synthesis in the reticulocyte lysate system. Similar results were obtained when in vitro translation experiments were performed with PAP at 0.1 ng/ml.
DISCUSSION
By random mutagenesis and selection in S. cerevisiae, we isolated PAP mutants with reduced toxicity. Molecular and biochemical characterization of these mutants showed that toxicity of PAP in vivo is not due solely to enzymatic activity. In vitro translation experiments demonstrated that PAP is synthesized as a 33-kDa precursor and is cotranslationally processed to a 32-kDa form. The processed form is still larger than the 29-kDa mature form and is not glycosylated, suggesting that PAP undergoes further proteolytic processing. Alignment of the PAP cDNA sequence with the protein sequence of the seed form of PAP (PAP-S) reveals that mature PAP is 29 amino acids shorter at its C terminus than the amino acid sequence predicted from the cDNA (7), suggesting that PAP undergoes further processing at its C terminus. Further evidence of C-terminal processing was obtained from x-ray structure analysis, which showed that mature PAP is 29 amino acids shorter at its C terminus than the sequence predicted from the cDNA (15) . PAP expressed in yeast appears to be fully processed to the mature form and its expression leads to complete growth arrest. The lethality of PAP to S. cerevisiae provided the basis for selection of mutations in PAP that abolish toxicity. A number of mutant alleles were sequenced and subsequently characterized into three groups: (i) mutants with altered enzymatic activity; (ii) processing deficient mutants; and (iii) C-terminal deletion mutants caused by nonsense or frameshift mutations.
The x-ray crystal structure of PAP has been solved recently and shows that PAP is homologous to the ricin A chain (15) . The two proteins are similar with respect to their folding patterns, the position of key active site residues, and a unique prominent cleft in their three-dimensional structure. Amino acid residues in this cleft, corresponding to Glu-177, Arg-180, Trp-211, and Asn-209 of the ricin A chain are shown to be conserved among several plant RIPs (16, 17) . Based on x-ray crystal structure analysis and site-directed mutagenesis studies, Ready et al. (18) proposed a mechanism for enzymatic activity of the ricin A chain in which Glu-177 is involved in transition-state stabilization. Consistent with this model is that conversion of negatively charged Glu-177 to Gln reduces activity almost 200-fold (19) , while conversion to Ala (E177A) reduces activity 20-fold (20) . Kinetic analysis showed that the E177A mutation affects kcat and not Km, consistent with the model that the carboxylate serves in transition-state stabilizaGenetics: Hur et aL tion (20) . One of the PAP mutants, HMNT123-2, has a change in the proposed active site cleft (E176V). The finding that the mutation in HMNT123-2 affects Glu-176 (equivalent to ricin Glu-177) lends support to the hypothesis that this glutamic acid residue in PAP, as has been demonstrated in ricin, is located at the enzymatic active site.
Our results show that alteration of amino acid residues outside the active site of PAP also reduces its toxicity. HMNT123-1 and HMNT124-1 both contained point mutations near the N terminus that affected processing of the PAP precursor. Although HMNT124-1 is nontoxic to yeast, it was enzymatically active in vitro, suggesting that the in vivo toxicity of PAP is not solely a function of its enzymatic activity. Since the mutations near the N terminus affect the processing of PAP in yeast, the mutant forms might be less toxic because their compartmentalization is altered.
Several mutants isolated contained nonsense mutations and one mutant contained a frameshift mutation, which led to premature termination of the growing polypeptide chain. One of these mutants, HMNT124-3, expressed sufficient levels of the mutant protein to test enzymatic activity. This mutant was enzymatically active in vitro; however, it did not affect the growth rate of yeast, suggesting that it is not capable of inhibiting protein synthesis in vivo. Since this mutant, as well as two others that had the same mutation, contained a 25-amino acid deletion at their C terminus, the sequences within the 25-amino acid segment appear to be critical for toxicity of PAP in vivo. Computer analysis of the PAP protein sequence by the functional motif data bases using the IntelliGenetics and University of Wisconsin Genetics Computer Group software programs reveals that the sequence at the C terminus of PAP, EIKPDVALLNYVGGSC, is homologous to the consensus sequence for the prokaryotic membrane lipoprotein lipid attachment site (21) . It is possible that the homologous sequences in PAP are involved in binding to membrane lipids. Similar mutations isolated in diphtheria toxin, which lead to premature termination of the B chain, affect binding of the toxin to the receptor and/or its translocation through the membrane (22) . In the case ofPseudomonas aeruginosa exotoxin A (PE), cholera toxin, and E. coli heatlabile toxin, the enzymatically active parts have C-terminal sequences that are critical for cytotoxicity (23) (24) (25) . However, it has been shown that cytotoxicity and enzymatic activity can be separated, since removal of C-terminal sequences of PE strongly reduces its cytotoxicity without affecting its enzymatic activity (26) . It is possible that the C-terminal sequences of PAP are involved in binding to phospholipids on endoplasmic reticulum membranes, which could facilitate its translocation into the cytosol where it can inhibit protein synthesis. The C-terminal deletion of 25 amino acids eliminates a Cys that is disulfide bonded to an N-terminal Cys, thus disrupting the disulfide bond, which might affect the conformation of the protein so that it cannot interact with membranes in vivo.
Unlike ricin A-chain mutations selected in yeast, which are predominantly at the active site (27) , we have isolated mutations outside the active site that eliminate the toxicity of PAP. Several mutants that had alterations outside the active site were enzymatically active in vitro, suggesting that cytotoxicity of PAP is not due solely to its enzymatic activity. Appropriate subcellular localization and interactions with membrane lipids may also be important for cytotoxicity of PAP. The nontoxic mutants were recovered with changes in the N-and C-terminal sequences, as well as the active site, suggesting that cytotoxicity depends on possibly different domains of the protein. Although PAP is a single-chain RIP isolated from plants, the mechanism of its toxicity may be more similar to the bacterial toxins than to the two-chain RIPs from plants. Understanding the structure-function relationships of PAP may provide basic information about the cytotoxicity of single-chain RIPs and may help elucidate the mechanistic aspects of their function.
